SIG
CBIO

Sargent Investment Group’s Crescent Biopharma CBIO Stock Holding History

Sargent Investment Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$28.2K – 221
2024
Q2 		$28.2K Sell
1,000
-80
-7% -$8.32K 0.01% 218
2024
Q1 		$324K Buy
1,080
+500
+86% +$149K 0.07% 147
2023
Q4 		$137K Hold
580
– – 0.03% 200
2023
Q3 		$87K Sell
580
-500
-46% -$78.9K 0.02% 195
2023
Q2 		$188K Hold
1,080
– – 0.05% 186
2023
Q1 		$135K Buy
+1,080
New +$243K 0.04% 188

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sargent Investment Group's CBIO Position: Q3 2024 in Review

Sargent Investment Group sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 1,000 shares — an estimated $28.2K sold.

Sargent Investment Group first reported a position in CBIO in Q1 2023 and held it in 6 quarters. The position peaked at $324K in Q1 2024. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

  • Sargent Investment Group reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
  • Sargent Investment Group sold 1,000 Crescent Biopharma shares in Q3 2024, an estimated $28.2K.
  • Sargent Investment Group first reported a position in Crescent Biopharma in Q1 2023 and held it in 6 quarters.
  • Sargent Investment Group's Crescent Biopharma position peaked at $324K in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on Sargent Investment Group's 13F filing for Q3 2024, filed 6 Nov 2024.